多粘菌素E、替加环素及比阿培南联合舒巴坦对多重耐药鲍曼不动杆菌肺炎治疗的对比研究

Clinical research of polymyxin E Tigecycline and biapenem combined with sulbactam in the treatment of multiple drug resistant acinetobacter baumannii pneumonia

目的:探究不同抗菌药物与舒巴坦联合治疗多重耐药鲍曼不动杆菌(Ab)肺炎的临床疗效。方法:将80例多重耐药Ab肺炎患者分为A组(30例)、B组(30例)和C组(20例),分别采用替加环素、多粘菌素E和比阿培南联合舒巴坦治疗,比较3组临床治疗效果。结果:A组和B组治疗总有效率(93.3%、90.0%)和细菌清除率(66.7%、66.3%)均高于C组(76.7%、40.0%)(P<0.05);A组和C组用药不良反应发生率(6.7%、5.0%)均低于B组(20.0%)(P<0.05)。结论:与多粘菌素E、比阿培南相比,替加环素联合舒巴坦治疗多重耐药Ab肺炎效果更为理想。

Objective：To explore the clinical effect of different antimicrobial agents combined with combined with sulbactam in the treatment of multiple drug-resistant AB pneumonia.Methods：80cases with multiple drug-resistant AB pneumonia were divided into the A group（30cases）and B group（30cases）and C group（20cases）randomly.They were given the Tigecycline polymyxin E and biapenem combined with sulbactam randomly.The clinical curative effects of the three groups were compared.Results：Total effective rate and bacterial clearance rate of group A and group B（93.3%,90.0%）（66.7%,66.3%）were higher than group C（76.7%,40.0%）,the difference was significant statistically significant（P0.05）.The drug adverse reaction rate of group A and group C（6.7%,5.0%）were lower than that of group B（20.0%）,the difference was significant statistically significant（P0.05）.Conclusion：Compared with polymyxin E and biapenem,Tigecycline combined with sulbactam on the treatment of multiple drug-resistant AB pneumonia has more ideal effect.